Smiths Group PLC
01 July 2004
News Release
London, 1 July 2004
Smiths strengthens medical business with acquisition of US respiratory care
device company for $55 million
Smiths Medical, one of the four operating divisions of Smiths Group plc, today
announced that it has completed the acquisition of the US respiratory care
device company DHD Healthcare, for a total of $55 million (£30 million) from
Riverside Capital of Cleveland, Ohio. DHD products are widely used to care for
the respiratory needs of patients in a variety of therapeutic and critical care
applications. Smiths satisfied the acquisition in cash.
Commenting on the acquisition, Keith Butler-Wheelhouse, chief executive of
Smiths Group said; 'This purchase once again underlines our intent to pursue a
strategy of profitable growth through the acquisition of high growth businesses
which complement or expand our product portfolio, and through investment in
research and development.'
Lawrence Kinet, managing director of Smiths Medical added: 'DHD's world class
respiratory products will complement and extend the Smiths Medical airway range
with high-growth, novel, respiratory care devices. We are pleased to welcome DHD
and its innovative, therapeutic products into Smiths Medical'.
DHD Healthcare, with 118 employees based in Wampsville, New York State, achieved
sales of $21.2 million in the last 12 months, with EBITDA at $6.1 million in the
same period.
Smiths Group designs and manufactures safety critical systems and products, and
has market leading positions in aerospace systems, detection systems, medical
devices, mechanical seals, and interconnect products.
For further information, visit www.smiths-group.com
Contact:
Smiths Group Investor Relations
Bernard Carey Russell Plumley:
Tel: +44 (0)20 8457 8403 Tel: +44 (0)20 8457 8203
Caroline Harris
Tel: +44 (0) 20 8457 8306
- ends -
Notes to editors:
DHD Healthcare's products include positive expiratory pressure therapy products
used in cases of chronic lung disease; incentive spirometers used
post-operatively to improve lung function: and devices used to help patients
inspire nebulised drugs from an inhaler. DHD's award-winning acapella(R) product
range has been enthusiastically received by patients around the world. In late
2003, DHD acquired a range of specialised nebulisation systems, incorporating
heaters and humidifiers, and oxygen delivery products.
The Riverside Company, with offices in New York, Cleveland, Dallas and San
Francisco, is the leading private equity firm investing in premier companies at
the smaller end of the middle market. Riverside's current portfolio numbers 26
companies. For more information, visit www.riversidecompany.com
Smiths Medical, a division of Smiths Group plc, is a world leader in the design,
manufacture, and distribution of medical devices used in infusion therapy,
including ambulatory infusion pumps, large volume infusion pumps, implantable
access systems, dialysis and infusion catheters, needles, and insulin delivery
systems.
This information is provided by RNS
The company news service from the London Stock Exchange
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.